secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORASURE TECHNOLOGIES INC (OSUR)
CIK:        0001116463
Form:       8-K
Filed at:   2023-02-14T23:59:59+00:00
Accession:  0000950170-23-002800
Event type: earnings
Sentiment:  positive
Materiality: 0.78
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OraSure Q4 revenue record $123.1M (+94% YoY); GAAP EPS $0.21; restructuring cuts 11% of workforce
--------------------------------------------------------------------------------

- Q4 revenue $123.1M record (+94% YoY); InteliSwab $88.9M (+502% YoY, +12% sequential).
- GAAP EPS $0.21, non-GAAP EPS $0.36; full-year GAAP EPS ($0.25), non-GAAP $0.34.
- Restructuring combines Molecular & Diagnostics units; 11% non-production role cuts, $15M annual savings by June 2023.
- Cash $110.8M, up $9M QoQ; guides Q1 revenue $125–130M (85–92% YoY growth).
- New federal InteliSwab contracts through Nov 2023; deal with Quest for saliva collection kits.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1116463/000095017023002800/0000950170-23-002800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1116463/000095017023002800/osur-20230214.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-002800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer